2019 Innovations in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Innovations in Cell, Gene, and Protein Therapies, Regenerative Medicine, Synthetic Biology, Epitranscriptomics, and CRISPR Editing” report has been added to ResearchAndMarkets.com’s offering.
The Life Science, Health & Wellness TechVision Opportunity Engine (TOE) details technology innovations across cell and gene therapies, regenerative medicine, synthetic biology, epitranscriptomics, CRISPR editing, biological computing, multiplexed assay and liquid biopsy platforms.
It also comprises emerging developments across mass spectrometry, vaccines, protein therapies, transplantation techniques, small molecule, and organ-on-a-chip technologies.
Key Topics Covered
- Cell Therapies
- Cynata Therapeutics
- David H. Koch Institute for Integrative Cancer Research at MIT
- Gotham Therapeutics
- Beam Therapeutics
- OMass Therapeutics
- Nightstar Therapeutics
- University of Minnesota
- SpeeDx Diagnostics
- Mammoth Biosciences
- Guardant Health
- Horizon Pharma
- Paragonix Technologies
- Achieve Life Sciences
- Neurocrine Biosciences
- Key Contacts
For more information about this report visit https://www.researchandmarkets.com/r/rozpgj
View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005771/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 04/16/2019 11:12 AM/DISC: 04/16/2019 11:12 AM